Clinical Trial Detail

NCT ID NCT02351037
Title A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pharmacyclics
Indications

acute myeloid leukemia

Therapies

Ibrutinib

Cytarabine

Age Groups: adult

No variant requirements are available.